|

Using a Blood Test to Monitor Metastatic Breast Cancer Treatment

RECRUITINGSponsored by Dr. Christopher Mueller
Actively Recruiting
SponsorDr. Christopher Mueller
Started2023-10-19
Est. completion2026-01
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05804578

Summary

The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria

-Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]

Conditions3

Breast CancerCancerMetastatic Breast Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.